Pfizer (NYSE:PFE) raised its full-year earnings outlook on Tuesday after reporting second-quarter results that surpassed Wall Street expectations, driving its shares up more than 3% in premarket trading.
The pharmaceutical giant posted earnings per share of $0.78 for Q2, comfortably ahead of the $0.57 consensus forecast. Revenue climbed 10% year-over-year to $14.7 billion, also exceeding expectations of $13.47 billion.
“Pfizer had another strong quarter of focused execution and we’re pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins,” said Dr. Albert Bourla, Chairman and CEO.
Reflecting the solid first-half performance, the company raised its full-year adjusted EPS forecast to a range of $2.90 to $3.10, up $0.10 at the midpoint from prior guidance and slightly below the analyst consensus of $3.01. Revenue guidance for 2025 was reaffirmed at $61.0 to $64.0 billion.
Pfizer said the revised outlook incorporates improved cost efficiencies, a lower tax rate, and currency tailwinds. It also factors in a one-time $1.35 billion R&D charge related to a licensing agreement with 3SBio, which is expected to reduce Q3 EPS by approximately $0.20.
Additionally, the company confirmed that its guidance accounts for existing tariffs and potential drug pricing changes following a late-July letter from President Trump.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.